Patient Support Excellence: Program Staffing and Budget

Study Overview

Facing declining sales from patent losses and payer pressures, the pharmaceutical sector is turning to patient support programs and activities to help drive clinical and commercial success. As pharma has invested in patient support programs, staffing and budget levels have increased but it is unclear what resource levels are appropriate - or increase effectiveness - for this rising function.

Best Practices, LLC conducted this study to generate reliable industry metrics on current patient support group staffing and budget levels. In particular, the study reviews current drivers for patient support programs, current staffing metrics and budget sources and levels. This benchmarking study will provide patient support leaders with metrics and insights they can use to assess their patient support operations' staffing and budget levels.

This study has small, medium and large company segments on some questions


Key Topics

• Patient Support in Pharma
• Staffing and Program Drivers
• Program Staffing
• Program Budget

• Reasons driving your organization to provide patient support programs
• Factors influencing the development of new patient support programs
• Factors influencing the level of staffing for patient support programs
• FTEs allocated to patient support for your area of responsibility and company-wide
• FTEs allocated to patient support for your area of responsibility and company-wide - segmented by self-rating of program effectiveness
• FTEs allocated to patient support for your area of responsibility and company-wide - segmented by patient support organizational structure
• Functional groups that provide funding for your patient support program
• Total budget for patient support initiatives for your area of responsibility and company-wide patient support
• Percentage of marketing budget allocated for patient support initiatives

• Brand Teams Principal Funding Source for Patient Support Programs: 47% of respondents said brand/product teams were their Patient Support programs’ principal funder. Company-wide business units were the next largest principal funder at 41%. Meanwhile, a majority said medical was not a contributor to their program.
• A majority of Patient Support programs rated as “Very Good” receive their primary funding from company-wide business units.
• Most of the Patient Support programs that were rated “Good” or “So-So” receive their primary funding from brand or product teams.
• By Company Size: LCS = 57% brand/product team is principal funder; MCS = 75% company-wide business units are principal funders; SCS = 50% company-wide business units are principal funder. (42%).
  
  

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Medical Device; Chemical


Companies Profiled:
Sanofi; Merck; GlaxoSmithKline ; Novo Nordisk; Daiichi Sankyo; Pfizer; Boehringer Ingelheim; AstraZeneca; Astellas; Baxter Healthcare; EMD Serono; Merck Serono; Celgene; UCB Pharma; Millenium; Dr Reddy's Laboratories; Roche; LEO Pharma; Horizon Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.